Skip to main content
. 2019 Oct 31;58(1):37–49. doi: 10.5414/CP203549

Figure 1. Study design. 5ARI = 5-α reductase inhibitor; AB = α-blocker; BPH = benign prostatic hyperplasia; DUT-TAM = dutasteride-tamsulosin; FDC = fixed-dose combination; MPR = medication possession ratio.

Figure 1.